Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Albireo Pharma Inc (ALBO)

Albireo Pharma Inc (ALBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the...

ALBO : 25.46 (-1.32%)
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.

ADIL : 2.34 (-6.02%)
ALBO : 25.46 (-1.32%)
Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance

– Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M – Unaudited cash of at least $248M, updates guidance with cash into 2024 – BOLD...

ALBO : 25.46 (-1.32%)
Albireo Announces Positive Topline Data from Phase 1 Study of A3907

– First oral, systemic ASBT inhibitor was safe and well tolerated – Secondary and exploratory objectives show favorable pharmacokinetics and systemic...

ALBO : 25.46 (-1.32%)
Albireo Presenting New Bylvay™ (odevixibat) Data at NASPGHAN 2021

– Data show significant correlations in serum bile acid reductions and long-term improvements in pruritus and sleep – Reductions in serum bile acids and...

ALBO : 25.46 (-1.32%)
Albireo Announces Changes to R&D Organization

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today...

ALBO : 25.46 (-1.32%)
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer

– New chief business officer to oversee Company’s corporate and business development strategy –...

ALBO : 25.46 (-1.32%)
Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ALBO : 25.46 (-1.32%)
Albireo Reports Q3 Financial Results and Business Update

– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 ’21 revenue of $1.1 million– – ASSERT & BOLD Phase 3 studies enrolling, on track...

ALBO : 25.46 (-1.32%)
Albireo to Report Third Quarter 2021 Financial Results on November 4

— Conference call and webcast to be held at 10:00 a.m. ET — ...

ALBO : 25.46 (-1.32%)

Barchart Exclusives

Hedging Inflation: Currencies, Kings, and Weather Derivatives
One of the most popular topics these days is US inflation, and with that attention turns to how to hedge against it. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar